Long Dissociation of Bictegravir from HIV-1 Integrase-DNA Complexes.
PMID: 33649107
2021
Antimicrobial agents and chemotherapy
Introduction: Likewise, cases of failure with emergent M184V and R263K were reported for DTG-plus-lamivudine dual therapy in the clinical trials GEMINI and ACTG5353.
HIV Drug Resistance Mutations Detection by Next-Generation Sequencing during Antiretroviral Therapy Interruption in China.
Abstract: In 49 patients that followed-up a median 10 months later, HIV drug resistance mutations at >20% frequency such as K103N, M184VI and P225H still existed, but with decreased frequencies.
Result: Although these variants still existed at follow-up, the frequencies of the mutations M184VI, K103N and P225H decreased over time, and most of them remained at frequencies of more than 20%.
Result: At baseline, mutations with a frequency of 20% and above were NRTI-related, such as M184VI (2.0%, 1/49), and NNRTI-related like K103N (14.3%, 7/49), E138AG (4.1%, 2/49),
Low Frequency of Integrase Inhibitor Resistance Mutations Among Therapy-Naive HIV Patients in Southeast China.
PMID: 33679129
2021
Drug design, development and therapy
Abstract: Two samples harbored the T215S, M184V and K70E mutations related to nucleoside RTIs (NRTIs).
Result: In one participant, two NRTIs-resistance mutations (M184V, K70E) were observed.
Result: The M184V mutation can contribute to resistance if present along with other major resistance mutations high level resistance to lamivudine (3TC) and emtricitabine, and low-level resistance to didanosine and abacavir.
Table: M184V
High Efficacy of Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in People with Suppressed HIV and Preexisting M184 V/I.
PMID: 33722682
2021
International journal of infectious diseases
Abstract: DISCUSSION: Despite high prevalence of M184V/I in antiretroviral therapy (ART) experienced patients, DTG treatment outcomes will likely not be adversely affected by this mutation.
Abstract: DTG-based regimens have to great extent been effective at maintaining viral suppression in treatment experienced PLWH carrying M184V/I.
Abstract: High genetic barrier to the development of resistance associated with DTG and progressive viral suppression in patients switched to DTG-based therapy with M184V/I, may encourage better DTG outcomes and help in curbing increasing levels of HIV drug resistance in LMICs.
Abstract: Lamivudine and emtricitabine associated M184V/I mutation is highly prevalent in PLWH and the majority of HIV infected individuals receiving DTG regimen
Tenofovir disoproxil fumarate and emtricitabine maintenance strategy in virologically controlled adults with low HIV-1 DNA: 48 week results from a randomized, open-label, non-inferiority trial.
PMID: 33724373
2021
The Journal of antimicrobial chemotherapy
Abstract: Six VFs occurred in the tenofovir disoproxil fumarate/emtricitabine arm (two with emerging mutations M184V and K65R) versus two in the control arm (ITT difference 3.5%, 95% CI -1.9 to 9.4).
Prevalence of M184V and K65R in proviral DNA from PBMCs in HIV-infected youths with lamivudine/emtricitabine exposure.
PMID: 33734374
2021
The Journal of antimicrobial chemotherapy
Abstract: In December 2019, the remaining three subjects carrying M184V/I in pDNA maintained suppressed viraemia, and two still used emtricitabine in ART.
Abstract: METHODS: We included vertically HIV-infected youths/young adults aged >=10 years in the Madrid Cohort of HIV-1 Infected Children and Adolescents, exposed to lamivudine and/or emtricitabine, with M184V/I and/or K65R/E/N in historic plasma samples, on antiretroviral therapy (ART), virologically suppressed (HIV-1 RNA <50 copies/mL), and with available PBMCs in the Spanish HIV BioBank.
Abstract: Nine (75%) youths did not present M184V/I in pDNA after at least 1 year of viral suppression.
Abstract: OBJECTIVES: We analysed the prevalence of PMID: 33788308
2021
Journal of medical virology
Abstract: The most common primary mutations found were M184V (29.5%), K103N (25%), M41L (9.8%), T215Y (8.3%), and G190A (8.3%).
Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study.
PMID: 34397746
2021
Journal of acquired immune deficiency syndromes (1999)
Result:
Result: Altogether, 68 participants with baseline NRTI resistance (including 50 with M184V/I) received B/F/TAF during the study and had postswitch virologic data.
Result: Among participants with M184V or I mutations at baseline 97% (30 of 31) on B/F/TAF and 95% (19 of 20) on SBR had HIV-1 RNA <50 copies/mL at week 24.
Result: At baseline, 13% (44 of 328) in the B/F/TAF group and 16% (26 of 165) in the SBR group had NRTI resistance, including 9% (31 of 328) and 12% (20 of 165) with M184V/I mutations in the B/F/TAF and SBR groups, respectively.
Result: One participant with M184V on B/F/TAF discontinued after the baseline visit and did not have virologic data at week 24.
Table: M184V/I
HIV-1 Drug Resistance and Genetic Transmission Networks Among MSM Failing Antiretroviral Therapy in South China 2014-2019.
Abstract: The most common DRMs were M184I/V (42.2%), followed by V179D/E (37.9%) and K65R (27.2%).
Discussion: M184I/V (42.2%) was the most prevalent NRTI-associated mutation, which might be caused
Discussion: A high frequency of K65R plus M184V/I (15.0%) was observed in this study, and K65R plus M184 V/I appeared sufficient to abrogate the NRTI activity of a regimen comprising ABC, TDF or D4T.
Discussion: In contrast, M184I/V increased susceptibility to Zidovudine (AZT), Stavudine (D4T) and TDF and slowed the emergence of AZT, D4T, and TDF resistance.
Dolutegravir in the long term in children and adolescents: frequent virological failure but rare acquired genotypic resistance.
HIV mutation literature information.
PMID: 
2021
Antimicrobial agents and chemotherapy
Browser Board
Co-occurred Entities
Filtrator
ViMRT